Trieu Vuong bought OTLC
November 17, 2025 · Form 4 insider transaction
Trieu Vuong bought 4,065 shares of Oncotelic Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
4,065
Price
$0.00
Total value
N/A
InsiderTrieu Vuong
Role—
SecuritySeries A Convertible Preferred Stock
Transaction codeA: Grant or award
Transaction dateNovember 17, 2025
Filing dateNovember 19, 2025
Shares owned after4,065
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis.; The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated November 17, 2025.